decoding cancer. one patient at a time.

We work with HEALTHCARE PROFESSIONALS and their PATIENTS

Laura van ‘t Veer,
Co-Founder, Agendia

Go behind the scenes to see 
how Agendia works.

Did you know that MammaPrint® is the ONLY breast cancer recurrence assay that has been PROSPECTIVELY proven to identify patients that may safely forgo chemotherapy?1

MammaPrint

97% of the Low Risk patient group, which primarily chose to forgo chemotherapy, were disease free after 5 years

Clinical
Classification

In the clinical High Risk group, 32% more patients could have been able to safely forgo chemotherapy if they were treated according to MammaPrint results

We strive to improve the quality of life for cancer patients, through molecular diagnostics, one patient at a time.

What Can We Do For You

medical options image

Agendia is a leader in the precision medicine era, bringing more effective, individualized treatment within reach of cancer patients. Leveraging the latest advancements in cancer research, Agendia’s suite of tests are designed to help physicians more accurately individualize and optimize cancer therapy.

Learn More
medical options image

If you’ve recently been diagnosed with breast cancer, it’s natural to have questions and concerns. The Patient section of this web site has been specifically designed to help you learn more about breast cancer and Agendia’s innovative, genomic tests that uncover more clinically actionable biology.  Our testing can provide you and your doctor with a detailed profile of your unique tumor to help make more informed treatment decisions.

Learn More

MammaPrint is the ONLY breast cancer recurrence assay backed by peer-reviewed, PROSPECTIVE outcome data.1  With NO Intermediate results2, MammaPrint gives you up to 39% MORE DEFINITIVE results3

Publications

Breast Cancer

News & Press

available worldwide

Contact us

Adam Brufsky, M.D.

Dr. Adam Brufsky discusses a study comparing MammaPrint® to the 21-gene assay and how BluePrint® molecular subtyping compares to traditional subtyping.

Adam Brufsky, M.D.

Dr. Adam Brufsky discusses a study comparing MammaPrint® to the 21-gene assay and how BluePrint® molecular subtyping compares to traditional subtyping.

Share This Video

Massimo Cristofanilli, M.D.

Dr. Massimo Cristofanilli discusses the benefits of using the MammaPrint®
70-Gene assay and the BluePrint® 80-Gene assay in the treatment process for breast cancer.

Massimo Cristofanilli, M.D.

Dr. Massimo Cristofanilli discusses the benefits of using the MammaPrint®
70-Gene assay and the BluePrint® 80-Gene assay in the treatment process for breast cancer.

Share This Video

Rene Bernards, Ph.D.

Dr. Rene Bernards discusses how breast cancer biology inspired the development of MammaPrint®

Rene Bernards, Ph.D.

Dr. Rene Bernards discusses how breast cancer biology inspired the development of MammaPrint®

Share This Video